Albany Molecular Research, Inc.

Bristol-myers Squibb Compnay

Oncotherapy Science, Incorporated

Wenge Cui

Shuang Liu

Richard Eric Olson

Bruce Francis Molino

Matthew L Isherwood

Min Hu

David Douglas Manning

Kassoum Nacro

Yusuke Nakamura

Peter Guzzo

Aruna Sambandam

Congxiang Zha

Joel R Walker

Yo Matsuo

David Jenkins

Shoji Hisada

Helene Decornez

Feryan Ahmed

Raymond Huntley

Robert Borbo Kargbo

Polivina Jolicia F Gauuan

Kristen N Fleming

Mahender Gurram

Zohreh Sajjadi-Hashemi

Bang-Chi Chen

Rulin Zhao

Bei Wang

Paul C Lobben

Rasidul Amin

Larry Yet

Yuh-lin Allen Yang

Kristen N Ryan

Peter R Guzzo

David M Jenkins

Polivina Jolicia Gauuan

Tricyclic compounds are provided. These compounds are PBK inhibitors, and are useful for the treatment of PBK related diseases, including cancer.

Tricyclic compounds and PBK inhibitors containing the same

The compounds of the present invention are represented by the following aryl- and heteroaryl-substituted tetrahydrobenzazepine and dihydrobenzazapine derivatives having formulae I(A-E) and formula (II): where the carbon atom designated * is in the R or S configuration, and the substituents X and R-Rare as defined herein.

Aryl- and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin

The aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepine derivative compounds of the present invention are represented by formulae 1(A-D) having the following structure: where the substituents X and R-Rare as defined herein. 

Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin

Disclosed are processes for preparing tetrahydroisoquinolines, intermediates useful in the preparation of tetrahydroisoquinolines, processes for preparing such intermediates, and a crystalline form of 6-[(4S)-2-methyl-4-(naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine. Also disclosed are pharmaceutical compositions comprising tetrahydroisoquinolines, methods of using tetrahydroisoquinolines in the treatment of depression and other conditions and methods for obtaining the crystalline form. One such intermediate has the following structure: 

Tetrahydroisoquinolines and intermediates therefor

The compounds of the present invention are represented by the following aryl- and heteroaryl-substituted tetrahydrobenzazepine and dihydrobenzazapine derivatives having formulae I(A-E) and formula (II):  where the carbon atom designated * is in the R or S configuration, and the substituents X and R-Rare as defined herein.

Growing community of inventors

Clifton Park, NY, United States of America

Wenge Cui